A recombinant Artemisia vulgaris pollen adjuvanted Art v 1 protein-based vaccine treats allergic rhinitis and bronchial asthma using pre- and co-seasonal ultrashort immunotherapy regimens in sensitized mice.
The study evaluated a vaccine for allergic rhinitis and bronchial asthma, using an ultrashort treatment regimen. The vaccine showed significant reduction in symptoms and immune response polarization, suggesting potential efficacy. Further safety studies are recommended.
- Babayeva M et al (2022).
- Front Immunol.
- PubMed:
- 36439113